Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D
Terry Roemer did a lot more than clean out his desk when he decided to leave Merck after a 13-year career developing antibodies at the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
